Pension and state funds dominating biomedical R&D investment: fiduciary duty and public health

BACKGROUND: Who benefits from the commercial biomedical research and development (R&D)? Patients-consumers and investors-shareholders have traditionally been viewed as two distinct groups with conflicting interests: shareholders seek maximum profits, patients - maximum clinical benefit. However,...

Descripción completa

Detalles Bibliográficos
Autor principal: Roller, Slavek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6833262/
https://www.ncbi.nlm.nih.gov/pubmed/31690328
http://dx.doi.org/10.1186/s12992-019-0490-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6833262/
https://www.ncbi.nlm.nih.gov/pubmed/31690328
http://dx.doi.org/10.1186/s12992-019-0490-x

Ejemplares similares